Compare Summit Therapeutics Inc (SMMT) vs Tapestry, Inc. (TPR) Price & Performance

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.

TPR trades at $115.82, up 2.14% today, with strong analyst support (73% buy ratings) and a $174.64 consensus price target suggesting 51% upside. The stock shows robust profitability with 77.82% gross margins and has beaten earnings estimates for three consecutive quarters. However, technical indicators signal bearish momentum, and 2025 net income declined significantly to $183M from prior years above $800M. Recent news highlights Coach's momentum and international growth in China and Europe.

The investment case balances strong brand performance and analyst optimism against execution risks and valuation concerns. Upside potential exists from earnings beats and international expansion, but investors face headwinds from Kate Spade performance issues, tariff pressures, and the stock's current bearish technical trend. The significant gap between current price and analyst targets presents opportunity if fundamental improvements materialize.